Blend CJC 1295 NO DAC 2mg with Ipamorelin 2mg

This blend combines two synthetic peptides: CJC-1295 NO-DAC and Ipamorelin, studied together in vitro for their interaction with two distinct receptor pathways involved in growth hormone signaling research.

CJC-1295 NO-DAC is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH) that engages the GHRH receptor, while Ipamorelin is a 5-amino-acid peptide that engages the growth hormone secretagogue receptor (GHS-R). This formulation does not contain the drug affinity complex (DAC) used in a related CJC-1295 variant.

Structural Distinction: NO-DAC Versus DAC-Conjugated Analogs

The DAC-conjugated form of CJC-1295 carries an added maleimidopropionic acid group that covalently binds circulating albumin, a modification designed to extend the molecule's presence in solution. The NO-DAC form used in this blend lacks this conjugation site entirely, leaving the 29-residue GHRH-analog sequence unmodified at its C-terminus.

Researchers selecting between these two structural variants for a given experimental design consider this conjugation difference a primary factor, since it changes the molecule's size, charge distribution, and behavior in size-exclusion or affinity-based analytical methods.

GHRH Receptor Binding Research

Structural and computational research has examined the dynamic properties of the GHRH receptor and the molecular determinants of GHRH binding, providing researchers a receptor-level framework for interpreting how unconjugated GHRH analogs like CJC-1295 NO-DAC are expected to engage this receptor.¹

Ipamorelin Structural Considerations

Ipamorelin's sequence includes D-2-naphthylalanine, a non-natural amino acid studied for its role in GHS-R binding affinity, along with an Aib (2-aminoisobutyric acid) residue at the N-terminus that is thought to add resistance to enzymatic degradation relative to standard amino acids.

Molar Mass Considerations for a Two-Component Blend

Because this vial contains two peptides of different molecular weights combined at a 1:1 mass ratio (2 mg each), the two components are not present in equal molar quantities despite their equal mass, since molar quantity depends on molecular weight as well as mass.

This distinction matters for any assay comparing molar potency or receptor occupancy between the two components, since researchers cannot assume equal mass corresponds to equal molar contribution from each peptide.

Storage and Handling in the Laboratory Setting

Because this blend contains two peptides with different degradation sensitivities, researchers generally treat the combined vial with the more conservative handling requirements of the two components rather than the average of the two.

Standard practice is sub-zero freezer storage of the lyophilized powder, since Ipamorelin's aromatic residues and CJC-1295 NO-DAC's longer chain length each introduce their own routes of degradation over time if stored improperly.

Important Notice

This product is intended exclusively for in vitro laboratory research and is not for human use or consumption. All findings referenced here are based on in vitro research, and have not been evaluated for safety or efficacy in humans. This product is strictly for laboratory use to explore biochemical mechanisms under controlled experimental conditions.

Product Information

Blue Sky Peptide's Blend CJC-1295 NO-DAC with Ipamorelin is available as a white lyophilized powder, with a concentration of 4 mg per vial.

References

1. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone-releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017;13(7):1313-1322.